Literature DB >> 27501829

Understanding the pathophysiology of the human TB lung granuloma using in vitro granuloma models.

Sudha Bhavanam1,2,1,3,4, Gina R Rayat1,2,1,3,4, Monika Keelan1,2,1,3,4, Dennis Kunimoto1,2,1,3,4, Steven J Drews1,2,1,3,4.   

Abstract

Tuberculosis remains a major human health threat that infects one in three individuals worldwide. Infection with Mycobacterium tuberculosis is a standoff between host and bacteria in the formation of a granuloma. This review will introduce a variety of bacterial and host factors that impact individual granuloma fates. The authors describe advances in the development of in vitro granuloma models, current evidence surrounding infection and granuloma development, and the applicability of existing in vitro models in the study of human disease. In vitro models of infection help improve our understanding of pathophysiology and allow for the discovery of other potential models of study.

Entities:  

Keywords:  Mycobacterium tuberculosis; dormancy; granuloma; host factors; in vitro models; infection; microbial factors; new discoveries

Mesh:

Year:  2016        PMID: 27501829     DOI: 10.2217/fmb-2016-0005

Source DB:  PubMed          Journal:  Future Microbiol        ISSN: 1746-0913            Impact factor:   3.165


  6 in total

1.  Specific Human and Candida Cellular Interactions Lead to Controlled or Persistent Infection Outcomes during Granuloma-Like Formation.

Authors:  Barbara Misme-Aucouturier; Marjorie Albassier; Nidia Alvarez-Rueda; Patrice Le Pape
Journal:  Infect Immun       Date:  2016-12-29       Impact factor: 3.441

2.  Photoclick Reaction Constructs Glutathione-Responsive Theranostic System for Anti-Tuberculosis.

Authors:  Judun Zheng; Xun Long; Hao Chen; Zhisheng Ji; Bowen Shu; Rui Yue; Yechun Liao; Shengchao Ma; Kun Qiao; Ying Liu; Yuhui Liao
Journal:  Front Mol Biosci       Date:  2022-02-14

3.  Structure-Based Virtual Screening of Benzaldehyde Thiosemicarbazone Derivatives against DNA Gyrase B of Mycobacterium tuberculosis.

Authors:  Andiyappan Kistan; Balakrishnan Anna Benedict; Sundaramoorthy Vasanthan; Alphonse PremKumar; Malathi Kullappan; Jenifer Mallavarpu Ambrose; Vishnu Priya Veeraraghavan; Gayathri Rengasamy; Krishna Mohan Surapaneni
Journal:  Evid Based Complement Alternat Med       Date:  2021-12-13       Impact factor: 2.629

4.  Inhibition of IL-17A by secukinumab shows no evidence of increased Mycobacterium tuberculosis infections.

Authors:  Michael Kammüller; Tsen-Fang Tsai; Christopher Em Griffiths; Nidhi Kapoor; Pappachan E Kolattukudy; Dominique Brees; Salah-Dine Chibout; Jorge Safi; Todd Fox
Journal:  Clin Transl Immunology       Date:  2017-08-25

Review 5.  Mycobacterium tuberculosis: An Adaptable Pathogen Associated With Multiple Human Diseases.

Authors:  Qiyao Chai; Yong Zhang; Cui Hua Liu
Journal:  Front Cell Infect Microbiol       Date:  2018-05-15       Impact factor: 5.293

6.  Characterization of immune responses of human PBMCs infected with Mycobacterium tuberculosis H37Ra: Impact of donor declared BCG vaccination history on immune responses and M. tuberculosis growth.

Authors:  Sudha Bhavanam; Gina R Rayat; Monika Keelan; Dennis Kunimoto; Steven J Drews
Journal:  PLoS One       Date:  2018-09-11       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.